Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Masahiro Seike, MD"'
Autor:
Takehiro Tozuka, MD, Rintaro Noro, MD, PhD, Keisuke Yoshida, PhD, Satoshi Takahashi, MD, PhD, Mariko Hirao, MD, Kuniko Matsuda, MD, Yasuhiro Kato, MD, Shinji Nakamichi, MD, PhD, Susumu Takeuchi, MD, PhD, Masaru Matsumoto, MD, PhD, Akihiko Miyanaga, MD, PhD, Shinobu Kunugi, MD, PhD, Kazufumi Honda, DDS, PhD, Jun Adachi, PhD, Masahiro Seike, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100668- (2024)
Introduction: Osimertinib is a standard treatment for patients with EGFR-mutant NSCLC. Although some osimertinib resistance mechanisms have been identified, nearly 50% of the mechanisms remain to be elucidated. This study was aimed at identifying non
Externí odkaz:
https://doaj.org/article/28ffabd2f77f47d7942680f03c8b460c
Autor:
Takehiro Tozuka, MD, Yuji Minegishi, MD, PhD, Ou Yamaguchi, MD, PhD, Kana Watanabe, MD, Yukihiro Toi, MD, Ryota Saito, MD, PhD, Yoshiaki Nagai, MD, PhD, Yosuke Tamura, MD, PhD, Tetsuaki Shoji, MD, PhD, Haruka Odagiri, MD, Noriyuki Ebi, MD, Kosuke Sakai, MD, PhD, Nobuhiro Kanaji, MD, PhD, Makoto Izumi, MD, Sayo Soda, MD, PhD, Satoshi Watanabe, MD, PhD, Satoshi Morita, PhD, Kunihiko Kobayashi, MD, PhD, Masahiro Seike, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100655- (2024)
Introduction: Immune checkpoint inhibitor (ICI)–based treatment has become standard treatment for patients with advanced NSCLC. We aimed to determine the survival benefit of upfront radiotherapy for brain metastases (BMs) in patients with NSCLC who
Externí odkaz:
https://doaj.org/article/266c2a21ca60472ab272511e35e74652
Autor:
Yuto Terashima, MD, Masaru Matsumoto, MD, PhD, Hiroki Iida, MD, Sae Takashima, MD, Aya Fukuizumi, MD, PhD, Susumu Takeuchi, MD, PhD, Akihiko Miyanaga, MD, PhD, Yasuhiro Terasaki, MD, PhD, Kazuo Kasahara, MD, PhD, Masahiro Seike, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 11, Pp 100578- (2023)
Introduction: Pervious studies reported the association of TTF-1 expression with the efficacy of platinum-doublet chemotherapy in combination with immune checkpoint inhibitors in advanced nonsquamous NSCLC. Nevertheless, the predictive value of exten
Externí odkaz:
https://doaj.org/article/a8d24f9941d1407ebf190954c5f35839
Autor:
Satoru Miura, MD, PhD, Makoto Nishio, MD, PhD, Hiroaki Akamatsu, MD, PhD, Yasushi Goto, MD, PhD, Hidetoshi Hayashi, MD, PhD, Akihiko Gemma, MD, PhD, Ichiro Yoshino, MD, PhD, Toshihiro Misumi, PhD, Akito Hata, MD, Osamu Hataji, MD, PhD, Kohei Fujita, MD, PhD, Masahiro Seike, MD, PhD, Noriko Yanagitani, MD, PhD, Kazumi Nishino, MD, PhD, Satoshi Hara, MD, Ryota Saito, MD, PhD, Masahide Mori, MD, PhD, Takeshi Tsuda, MD, Shunichiro Iwasawa, MD, PhD, Shintaro Nakagawa, MSc, Tetsuya Mitsudomi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 3, Pp 100484- (2023)
Introduction: The efficacy and safety of atezolizumab in previously treated patients with NSCLC have been established in the registrational phase 3 OAK trial. In this study, we evaluated the effectiveness and safety of atezolizumab monotherapy in a l
Externí odkaz:
https://doaj.org/article/cf2603aadeec484c8f8d98e2ec1d639b
Autor:
Hideki Terai, MD, Kenzo Soejima, MD, Asanao Shimokawa, PhD, Hidehito Horinouchi, MD, Junichi Shimizu, MD, Tetsunari Hase, MD, Ryota Kanemaru, MD, Kana Watanabe, MD, Kiichiro Ninomiya, MD, Naoko Aragane, MD, Noriko Yanagitani, MD, Yoshihiko Sakata, MD, Masahiro Seike, MD, Daichi Fujimoto, MD, Masashi Kasajima, MD, Akihito Kubo, MD, Sojiro Kusumoto, MD, Yoshitaka Oyamada, MD, Keiichi Fujiwara, MD, Masahide Mori, MD, Midori Hashimoto, MD, Masato Shingyoji, MD, Masahiro Kodani, MD, Jin Sakamoto, MD, Toshihiko Agatsuma, MD, Kosuke Kashiwabara, MD, Minehiko Inomata, MD, Motoko Tachihara, MD, Kazuhisa Tanaka, MD, Kenji Hayashihara, MD, Nobuyuki Koyama, MD, Kaoru Matsui, MD, Koichi Minato, MD, Daisuke Jingu, MD, Hiroyuki Sakashita, MD, Satoshi Hara, MD, Tomoyuki Naito, MD, Asuka Okada, MD, Masayuki Tanahashi, MD, Yuki Sato, MD, Koichiro Asano, MD, Takayuki Takeda, MD, Kensuke Nakazawa, MD, Toshiyuki Harada, MD, Kazuhiko Shibata, MD, Tatsuo Kato, MD, Etsuo Miyaoka, PhD, Ichiro Yoshino, MD, Akihiko Gemma, MD, Tetsuya Mitsudomi, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 11, Pp 100404- (2022)
Introduction: Pembrolizumab is a programmed death-ligand 1 inhibitor that was initially indicated for monotherapy in patients with advanced lung cancer. The Japanese Lung Cancer Society conducted an observational study on pembrolizumab using confirma
Externí odkaz:
https://doaj.org/article/67a827674fcd4c4087dafceff77375be
Autor:
Aya Fukuizumi, MD, Rintaro Noro, MD, PhD, Masahiro Seike, MD, PhD, Akihiko Miyanaga, MD, PhD, Yuji Minegishi, MD, PhD, Miwako Omori, MD, Mamiko Hirao, Kuniko Matsuda, Shinobu Kunugi, MD, PhD, Kazutaka Nishiwaki, Masahiro Morimoto, Haruka Motohashi, Hayato Ohwada, PhD, Jitsuo Usuda, MD, PhD, Akihiko Gemma, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 11, Pp 100232- (2021)
Introduction: To investigate the genomic profiles of patients with lung cancer with idiopathic pulmonary fibrosis (IPF-LC), mechanism of carcinogenesis, and potential therapeutic targets. Methods: We analyzed 29 matched, surgically resected, cancerou
Externí odkaz:
https://doaj.org/article/790906db2fa7483283e2b97f1365bd03